Documents and (6) (4) used for distribution of the(6) (4) drug products are deficient.
Inspection Record
GSK Vaccines GmbH — FDA 483 Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
Separate or defined areas to prevent mix-ups are deficient.
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
- ROSLIN CELL THERAPIES LIMITED2025-01-21 · US FDASimilar to finding 4 Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.
- Sanofi Pasteur2023-09-29 · US FDASimilar to finding 4 Procedures designed to prevent microbiological contamination ofdrug products purporting to be sterile are not followed.
- Eugia Steriles Private Limited2026-06-19 · US FDASimilar to finding 4 Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.
- Biocon Biologics Limited2022-08-26 · US FDASimilar to finding 4 Procedures designed to prevent microbiological contamination ofdrug products purporting to be sterile are not established and followed.
- ADMA Biologics, Inc2024-12-11 · US FDASimilar to finding 2 There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.